Gland Pharma Q2 Results: Net profit jumps 58% on strong business execution, CDMO revenue up 31%

Gland Pharma reported a 58.2% year-on-year jump in Q2 FY27 net profit to ₹291 crore, while revenue grew 23.3% to ₹1,834 crore. EBITDA surged 54.1% to ₹484 crore, with margins expanding to 26.4%. The CDMO business grew 31%, while Critical Injectables revenue increased 18%.